EQRXW 0.00 EQRx, Inc.
| Range: | 0.0439-0.064 | Vol Avg: | 0 | Last Div: | 0 | Changes: | -0.01 |
| Beta: | 0 | Cap: | 1.14B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Dec 20 2021 | Empoloyees: | 216 | ||
| CUSIP: | 26886C115 | CIK: | 0001843762 | ISIN: | Country: | US | |
| CEO: | Mr. Alexis A. Borisy A.M. | Website: | https://www.eqrx.com | ||||
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer. The company has partnerships with Exscientia and AbCellera Biologics Inc. EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow